EUCTR2010-021370-11-DE进行中（未招募）1 期
An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy. - MARC-2
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- iOMEDICO AG
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Each patient must meet the following criteria to be enrolled:
- •1.Provide written informed consent
- •2.Aged 18 years and above
- •3.Histologically or cytologically confirmed predominantly clear cell renal cell carcinoma
- •4.Metastatic disease documented by CT or MRI (histological confirmation not mandatory but wishful)
- •5.Patients with or without nephrectomy (partial or total)
- •6.Patients with at least one measurable lesion at baseline according to RECIST criteria 1.1
- •7.Failure of exactly one prior VEGFR-TKI therapy (e.g. sunitinib, sorafenib, pazopanib) for metastatic renal cell carcinoma
- •8.ECOG 0-2
- •9.Hemoglobin = 9.0 g/dL
- •10.Platelet count =75,000/µL
- •11.Absolute neutrophil count =1,5x109/l
- •12.Serum creatinine < 2.5 x ULN
- •13.Liver function: Serum bilirubin = 1.5 x ULN, AST or ALT = 2.5 x ULN. For patients with liver metastasis: AST and ALT = 5x ULN
- •14.Able to swallow the study drug whole as a tablet
- •15.Expected life expectancy of at least 6 months
- •16.Women of childbearing potential must have had a negative serum pregnancy test within 14 days prior to the administration of the study treatment or must have a documented condition that prohibits pregnancy (e.g. hysterectomy, post-menopausal).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Patients who meet any of the following criteria will be excluded from the study:
- •1.Patients who have received >1 prior VEGFR-TKI therapy or prior therapy with bevacizumab +/- interferon.
- •2.VEGFR-TKI therapy within 14 days prior to start of study drug
- •3.Patients who have previously received systemic mTOR inhibitors (sirolimus, temsirolimus, everolimus).
- •4.Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients.
- •5.Any condition which, in the opinion of the investigator, would preclude participation in this trial
- •6.Patients within 4 weeks post-major surgery (e.g., intra-thoracic, intra-abdominal or intrapelvic), open biopsy, or significant traumatic injury to avoid wound healing complications. Minor procedures and percutaneous biopsies or placement of vascular access device require 7 days prior to study entry.
- •7.Patients who had radiation therapy as part of the curative treatment within 4 weeks prior to start of study treatment. Palliative radiotherapy to bone lesions within 2 weeks prior to study treatment start.
- •8.Patients in anticipation of the need for major surgical procedure during the course of the study.
- •9.Patients with a serious non-healing wound, ulcer, or bone fracture.
- •10.Patients with a history of seizure(s) not controlled with standard medical therapy.
- •11.History or clinical evidence of central nervous system (CNS) metastases. Subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and meet all 3 of the following criteria are eligible:
- •a) are asymptomatic and,
- •b) have had no evidence of active CNS metastases for = 3 months prior to enrolment (inactive/controlled CNS metastases are allowed) and,
- •c) have no requirement for steroids or enzyme-inducing anticonvulsants (e.g. carbamazepine, phenobarbital, phenytoin)
- •12.Patients receiving chronic systemic treatment with corticosteroids (dose of > 10 mg/day methylprednisone equivalent) or another immunosuppressive agent. Inhaled and topical steroids are acceptable.
- •13.Poorly controlled diabetes as defined by fasting serum glucose >2.0 x ULN.
- •14.Active (acute or chronic) or uncontrolled infection of bacterial, mycotic or viral genesis.
- •15.Liver disease such as chronic active hepatitis or chronic persistent hepatitis.
- •16.Impaired liver function classified as Child-Pugh class C.
- •17.Patients with a known history of HIV seropositivity.
- •18.Patients with active bleeding disorders.
- •19.Patients who have any severe and/or uncontrolled medical conditions or other conditions within the past 12 months that could affect their participation in the study or any disorders that impair the ability to evaluate the patient or for the patient to complete the study according to the investigators assessment.
- •20.Patients who have a history of another primary malignancy and off treatment for = 3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of the uterine cervix or breast, and localized cancer of the bladder (T1) and prostate (T1 - T2).
- •21.Female patients who are pregnant or breast feeding.
- •22. Men and women of reproductive potential who are not using highly effective birth control methods. Oral contraceptives for female patients and barrier contraceptives are not acceptable. For definition of highly effective birth control methods please refer to section 12.3.6 of this protocol.
- •23.Patients who are using other investigational agents or w
研究者
相似试验
已完成
不适用
An open label, single dose study to assess the pharmacokinetics of a microdose of recombinant human placental alkaline phosphatase (hRESCAP, part 1) followed by a randomized, double-blind, placebo-controlled, parallel, single ascending dose, first-in-human study to assess safety and tolerability of hRESCAP (part 2) in healthy male volunteersinflammation1000381610004018NL-OMON38993Centre for Human Drug Research15
进行中（未招募）
1 期
An open label, multicenter, Phase I/II study of pazopanib in combination with paclitaxel in first line treatment of subjects with stage IIIBwet/IV non-small cell lung cancerPart I: Subjects with histologically or cytologically confirmed diagnosis of advanced solid tumours for which there is no standard therapy or for whom paclitaxel is standard therapy. Part II: Stage IIIB wet (with histologically- or cytologically-confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1 Level: LLT Classification code 10029521 Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1 Level: LLT Classification code 10029522 Term: Non-small cell lung cancer stage IVEUCTR2009-010571-24-GBGlaxoSmithKline Research & Development Limited
进行中（未招募）
1 期
An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NAThe following tumors are included:1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelson’s syndromeMedDRA version: 9.1Level: LLTClassification code 10062476Term: Neuroendocrine tumorEUCTR2008-007348-32-FRovartis Pharma Services AG100
进行中（未招募）
不适用
An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - ND1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelsons syndromeMedDRA version: 9.1Level: LLTClassification code 10051747EUCTR2008-007348-32-ITOVARTIS FARMA70
进行中（未招募）
1 期
An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NAEUCTR2008-007348-32-DEovartis Pharma Services AG120